FDA
-
-
-
-
-
-
-
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
-
-
-
-
-
-
-
Pre-Open 12/03: (BOLD) (VRAY) (ALDX) Higher (CBL) (CARA) (CLF) Lower (more...)
-
-
-
-
-
-
-
Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Audentes Therapeutics to Provide Update on New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, from the 23rd International Annua
-
-
-
-
-
-
-
Audentes Therapeutics (BOLD) Announces Update on ASPIRO Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
-
-
-
-
-
-
-
Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
-
323,592 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

